Skip to main content

Advertisement

SpringerLink
Log in

The Management of Nausea and Vomiting Not Related to Anticancer Therapy in Patients with Cancer

  • Palliative and Supportive Care (MP Davis, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

In cancer patients, the management of nausea and vomiting that is not directly related to treatment is challenging. Much current practice is based on expert opinion and anecdote. Fortunately, over recent years, a number of quality trials have been undertaken to strengthen the evidence base that guides the care of our patients with these distressing symptoms. Much is still unknown however. In this article, we present the latest literature that addresses some of the outstanding issues.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Ang SK, Shoemaker LK, Davis MP. Nausea and vomiting in advanced cancer. Am J Hosp Palliat Care. 2010;27(3):219–25.

    Article  PubMed  Google Scholar 

  2. Davis MP, Walsh D. Treatment of nausea and vomiting in advanced cancer. Support Care Cancer. 2000;8(6):444–52.

    Article  CAS  PubMed  Google Scholar 

  3. Mystakidou K, Befon S, Trifyllis J, Liossi C, Papadimitriou J. Tropisetron versus metoclopramide in the control of emesis in far-advanced cancer. Oncologist. 1997;2(5):319–23.

    Article  CAS  PubMed  Google Scholar 

  4. Mystakidou K, Befon S, Liossi C, Vlachos L. Comparison of tropisetron and chlorpromazine combinations in the control of nausea and vomiting of patients with advanced cancer. J Pain Symptom Manag. 1998;15(3):176–84.

    Article  CAS  Google Scholar 

  5. Glare P, Pereira G, Kristjanson LJ, Stockler M, Tattersall M. Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer. Support Care Cancer. 2004;12(6):432–40.

    Article  PubMed  Google Scholar 

  6. Dietz I, Schmitz A, Lampey I, Schulz C. Evidence for the use of Levomepromazine for symptom control in the palliative care setting: a systematic review. BMC Palliat Care. 2013;12:2.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Cox L, Darvill E, Dorman S. Levomepromazine for nausea and vomiting in palliative care. Cochrane Database Syst Rev. 2015;11:CD009420.

    Google Scholar 

  8. •• Hardy JR, Skerman H, Philip J, et al. Methotrimeprazine versus haloperidol in palliative care patients with cancer-related nausea: a randomised, double-blind controlled trial. BMJ Open. 2019;9(9):e029942 A quality multicentre randomized controlled trial defing the antiemetic activity of levomepromazine.

    Article  PubMed  PubMed Central  Google Scholar 

  9. McCabe HL, Maraveyas A. Subcutaneous levomepromazine rescue (SLR) for high grade delayed chemotherapy-induced emesis (DCIE). Anticancer Res. 2003;23(6D):5209–12.

    CAS  PubMed  Google Scholar 

  10. ASCCemesis in advanced cancer patients: an open-label study. Palliat Med 2005; 19(1): 71–5.

  11. Ghaemi SN, Goodwin FK. Use of atypical antipsychotic agents in bipolar and schizoaffective disorders: review of the empirical literature. J Clin Psychopharmacol. 1999;19(4):354–61.

    Article  CAS  PubMed  Google Scholar 

  12. Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull. 1999;25(2):201–22.

    Article  CAS  PubMed  Google Scholar 

  13. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, et al. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999;37(1):107–22.

    Article  CAS  PubMed  Google Scholar 

  14. Bymaster F, Perry KW, Nelson DL, et al. Olanzapine: a basic science update. Br J Psychiatry Suppl. 1999;37:36–40.

    Article  Google Scholar 

  15. Zhang W, Bymaster FP. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology. 1999;141(3):267–78.

    Article  CAS  PubMed  Google Scholar 

  16. Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38(24):2782–97.

    Article  CAS  PubMed  Google Scholar 

  17. •• Sutherland A, Naessens K, Plugge E, et al. Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev. 2018;9:CD012555 This reviewsupports the role of olanzapine as an antiemetic.

    PubMed  Google Scholar 

  18. Zhou JG, Huang L, Jin SH, et al. Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials. ESMO Open. 2020;5(1):e000621.

  19. Navari RM. Nausea and vomiting in advanced cancer. Curr Treat Options in Oncol. 2020;21(2):14.

    Article  Google Scholar 

  20. Kaneishi K, Imai K, Nishimura K, Sakurai N, Kohara H, Ishiki H, et al. Olanzapine versus metoclopramide for treatment of nausea and vomiting in advanced cancer patients with incomplete malignant bowel obstruction. J Palliat Med. 2020;23(7):880–1.

    Article  PubMed  Google Scholar 

  21. Harder S, Groenvold M, Isaksen J, Sigaard J, Frandsen KB, Neergaard MA, et al. Antiemetic use of olanzapine in patients with advanced cancer: results from an open-label multicenter study. Support Care Cancer. 2019;27(8):2849–56.

    Article  PubMed  Google Scholar 

  22. Kaneishi K, Kawabata M, Morita T. Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction. J Pain Symptom Manag. 2012;44(4):604–7.

    Article  CAS  Google Scholar 

  23. Srivastava M, Brito-Dellan N, Davis MP, Leach M, Lagman R. Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manag. 2003;25(6):578–82.

    Article  Google Scholar 

  24. Passik SD, Lundberg J, Kirsh KL, Theobald D, Donaghy K, Holtsclaw E, et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manag. 2002;23(6):526–32.

    Article  CAS  Google Scholar 

  25. Saudemont G, Prod’Homme C, Da Silva A, et al. The use of olanzapine as an antiemetic in palliative medicine: a systematic review of the literature. BMC Palliat Care. 2020;19(1):56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Navari RM, Pywell CM, Le-Rademacher JG, et al. Olanzapine for the treatment of advanced cancer-related chronic nausea and/or vomiting: a randomized pilot trial. JAMA Oncol. 2020;6:895.

    Article  PubMed  Google Scholar 

  27. Suzuki M, Komuro K, Ohara K. Olanzapine and betamethasone are effective for the treatment of nausea and vomiting due to metastatic brain tumors of rectal cancer. Case Rep Gastroenterol. 2014;8(1):13–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Jackson WC, Tavernier L. Olanzapine for intractable nausea in palliative care patients. J Palliat Med. 2003;6(2):251–5.

    Article  PubMed  Google Scholar 

  29. Shinjo T, Okada M. Olanzapine use in cancer patients for refractory vomiting. Gan To Kagaku Ryoho. 2006;33(3):349–52.

    CAS  PubMed  Google Scholar 

  30. Elsayem A, Bush SH, Munsell MF, Curry E III, Calderon BB, Paraskevopoulos T, et al. Subcutaneous olanzapine for hyperactive or mixed delirium in patients with advanced cancer: a preliminary study. J Pain Symptom Manag. 2010;40(5):774–82.

    Article  CAS  Google Scholar 

  31. Lorenzo MP, Burgess J, Darko W. Intravenous olanzapine in a critically ill patient: an evolving route of administration. Hosp Pharm. 2020;55(2):108–11.

    Article  PubMed  Google Scholar 

  32. Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35(28):3240–61.

    Article  CAS  PubMed  Google Scholar 

  33. Bruera E, Moyano JR, Sala R, Rico MA, Bosnjak S, Bertolino M, et al. Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial. J Pain Symptom Manag. 2004;28(4):381–8.

    Article  CAS  Google Scholar 

  34. Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT, et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol. 2013;31(25):3076–82.

    Article  CAS  PubMed  Google Scholar 

  35. • Vayne-Bossert P, Haywood A, Good P, Khan S, Rickett K, Jenkins-Marsh S, et al. Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemo- or radiotherapy, or surgery). Cochrane Libr. https://doi.org/10.1002/14651858.CD012002 Cochrane review on the role of corticosteroids for nausea not related to treatment.

  36. Wilkie G, Sakr B, Rizack T. Medical marijuana use in oncology: a review. JAMA Oncol. 2016;2(5):670–5.

    Article  PubMed  Google Scholar 

  37. Inglet S, Winter B, Yost SE, Entringer S, Lian A, Biksacky M, et al. Clinical data for the use of cannabis-based treatments: a comprehensive review of the literature. Ann Pharmacother. 2020;54(11):1109–43.

    Article  PubMed  Google Scholar 

  38. Mucke M, Weier M, Carter C, et al. Systematic review and meta-analysis of cannabinoids in palliative medicine. J Cachexia Sarcopenia Muscle. 2018;9(2):220–34.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Zhornitsky S, Potvin S. Cannabidiol in humans-the quest for therapeutic targets. Pharmaceuticals (Basel). 2012;5(5):529–52.

    Article  CAS  Google Scholar 

  40. •• Walsh D, Davis M, Ripamonti C, Bruera E, Davies A, Molassiotis A. Updated MASCC/ESMO consensus recommendations: management of nausea and vomiting in advanced cancer. Support Care Cancer 2017. 2016;25(1):333–40 Evidence-based guidelines for the management of nausea and vomiting not related to treatment.

    Article  Google Scholar 

  41. •• Hardy J, Skerman H, Glare P, et al. A randomized open-label study of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with advanced cancer and nausea not related to anticancer treatment. BMC Cancer. 2018;18(1):510 A paper that challenges the long-held views towards the best model for managing nausea and vomiting in palliative care.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Hardy JR, O’Shea A, White C, Gilshenan K, Welch L, Douglas C. The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer. J Pain Symptom Manag. 2010;40(1):111–6.

    Article  CAS  Google Scholar 

  43. Kumar G, Hayes KA, Clark R. Efficacy of a scheduled IV cocktail of antiemetics for the palliation of nausea and vomiting in a hospice population. Am J Hosp Palliat Care. 2008;25(3):184–9.

    Article  PubMed  Google Scholar 

  44. Weschules DJ. Tolerability of the compound ABHR in hospice patients. J Palliat Med. 2005;8(6):1135–43.

    Article  Google Scholar 

  45. Bleicher J, Bhaskara A, Huyck T, Constantino S, Bardia A, Loprinzi CL, et al. Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea/vomiting: results of two pilot trials. J Support Oncol. 2008;6(1):27–32.

    CAS  PubMed  Google Scholar 

  46. Fletcher DS, Coyne PJ, Dodson PW, Parker GG, Wan W, Smith TJ. A randomized trial of the effectiveness of topical “ABH Gel” (Ativan((R)), Benadryl((R)), Haldol((R))) vs. placebo in cancer patients with nausea. J Pain Symptom Manag. 2014;48(5):797–803.

    Article  Google Scholar 

  47. Smith TJ, Ritter JK, Poklis JL, Fletcher D, Coyne PJ, Dodson P, et al. ABH gel is not absorbed from the skin of normal volunteers. J Pain Symptom Manag. 2012;43(5):961–6.

    Article  CAS  Google Scholar 

  48. Davis MP, Hallerberg G, Palliative Medicine Study Group of the Multinational Association of Supportive Care in C. A systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy or radiation. J Pain Symptom Manag. 2010;39(4):756–67.

    Article  Google Scholar 

  49. • Feuer DJ, Broadley KE. Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer . Cochrane Database Syst Rev. 2000;2000(2):CD001219.This oft quoted paper is the basis for the standard use of dexamethasone in malignant bowel obstruction, even though both studies included were underpowered.

  50. Berger J, Lester P, Rodrigues L. Medical therapy of malignant bowel obstruction with octreotide, dexamethasone, and metoclopramide. Am J Hosp Palliat Care. 2016;33(4):407–10.

    Article  PubMed  Google Scholar 

  51. Tuca A, Roca R, Sala C, Porta J, Serrano G, González-Barboteo J, et al. Efficacy of granisetron in the antiemetic control of nonsurgical intestinal obstruction in advanced cancer: a phase II clinical trial. J Pain Symptom Manag. 2009;37(2):259–70.

    Article  CAS  Google Scholar 

  52. Obita GP, Boland EG, Currow DC, Johnson MJ, Boland JW. Somatostatin analogues compared with placebo and other pharmacologic agents in the management of symptoms of inoperable malignant bowel obstruction: a systematic review. J Pain Symptom Manag. 2016;52(6):901–19 e1.

  53. Currow DC, Quinn S, Agar M, Fazekas B, Hardy J, McCaffrey N, et al. Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction. J Pain Symptom Manag. 2015;49(5):814–21.

    Article  Google Scholar 

  54. Mercadante S. Octreotide for malignant bowel obstruction: commentary on Currow et al. J Pain Symptom Manag. 2015;49(5):813.

    Article  Google Scholar 

  55. Minoura T, Takeuchi M, Morita T, Kawakami K. Practice patterns of medications for patients with malignant bowel obstruction using a nationwide claims database and the association between treatment outcomes and concomitant use of H2-blockers/proton pump inhibitors and corticosteroids with octreotide. J Pain Symptom Manag. 2018;55(2):413–9 e2.

  56. Wey W, Mian M, Calabrese R, Walter M. Palliative medicine management of inoperable malignant bowel obstruction with ‘triple therapy’: dexamethasone,octreotide and metoclopramide at a comprehensive cancer center. J Pain Symptom Manag. 2020;59(2):552–3.

    Article  Google Scholar 

  57. Joyce WP, Delaney PV, Gorey TF, Fitzpatrick JM. The value of water-soluble contrast radiology in the management of acute small bowel obstruction. Ann R Coll Surg Engl. 1992;74(6):422–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Hardy J, Daly S, McQuade B, Albertsson M, Chimontsi-Kypriou V, Stathopoulos G, et al. A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients. Support Care Cancer. 2002;10(3):231–6.

    Article  CAS  PubMed  Google Scholar 

  59. Giusti R, Mazzotta M, Filetti M, Daniele G, Tsukuura H, Ficorella C, et al. Prophylactic use of antiemetics for prevention of opioid-induced nausea and vomiting: a survey about Italian physicians’ practice. Support Care Cancer. 2019;27(9):3531–5.

    Article  PubMed  Google Scholar 

  60. Laugsand EA, Kaasa S, Klepstad P. Management of opioid-induced nausea and vomiting in cancer patients: systematic review and evidence-based recommendations. Palliat Med. 2011;25(5):442–53.

    Article  PubMed  Google Scholar 

  61. Sato J, Tanaka R, Ishikawa H, Suzuki T, Shino M. A preliminary study of the effect of naldemedine tosylate on opioid-induced nausea and vomiting. Support Care Cancer. 2020;28(3):1083–8.

    Article  PubMed  Google Scholar 

  62. Carlisle JB, Stevenson CA. Drugs for preventing postoperative nausea and vomiting. Cochrane Database Syst Rev. 2006;3:CD004125.

    Google Scholar 

  63. O’Brien CM, Titley G, Whitehurst P. A comparison of cyclizine, ondansetron and placebo as prophylaxis against postoperative nausea and vomiting in children. Anaesthesia. 2003;58(7):707–11.

    Article  PubMed  Google Scholar 

  64. Nortcliffe SA, Shah J, Buggy DJ. Prevention of postoperative nausea and vomiting after spinal morphine for Caesarean section: comparison of cyclizine, dexamethasone and placebo. Br J Anaesth. 2003;90(5):665–70.

    Article  CAS  PubMed  Google Scholar 

  65. Woodfield J, St George EJ. Post-operative cyclizine misuse. Scott Med J. 2013;58(4):e1–2.

    Article  CAS  PubMed  Google Scholar 

  66. Bailey F, Davies A. The misuse/abuse of antihistamine antiemetic medication (cyclizine) by cancer patients. Palliat Med. 2008;22(7):869–71.

    Article  CAS  PubMed  Google Scholar 

  67. Glare P, Miller J, Nikolova T, Tickoo R. Treating nausea and vomiting in palliative care: a review. Clin Interv Aging. 2011;6:243–59.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Pedersen L, Klysner R. Antagonism of selective serotonin reuptake inhibitor-induced nausea by mirtazapine. Int Clin Psychopharmacol. 1997;12(1):59–60.

    Article  CAS  PubMed  Google Scholar 

  69. Yin J, Song J, Lei Y, Xu X, Chen JD. Prokinetic effects of mirtazapine on gastrointestinal transit. Am J Physiol Gastrointest Liver Physiol. 2014;306(9):G796–801.

    Article  CAS  PubMed  Google Scholar 

  70. Cao J, Ouyang Q, Wang S, Ragaz J, Wang X, Teng Y, et al. Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial. Investig New Drugs. 2020;38(2):507–14.

    Article  CAS  Google Scholar 

  71. Chang FL, Ho ST, Sheen MJ. Efficacy of mirtazapine in preventing intrathecal morphine-induced nausea and vomiting after orthopaedic surgery*. Anaesthesia. 2010;65(12):1206–11.

    Article  CAS  PubMed  Google Scholar 

  72. Chen CC, Lin CS, Ko YP, Hung YC, Lao HC, Hsu YW. Premedication with mirtazapine reduces preoperative anxiety and postoperative nausea and vomiting. Anesth Analg. 2008;106(1):109–13 table of contents.

  73. Huerta S, Siddiqui A. Intractable nausea and vomiting following Roux-en-Y gastric bypass: role of mirtazapine. Obes Surg. 2006;16(10):1399.

    Article  PubMed  Google Scholar 

  74. Pae CU. Low-dose mirtazapine may be successful treatment option for severe nausea and vomiting. Prog Neuro-Psychopharmacol Biol Psychiatry. 2006;30(6):1143–5.

    Article  CAS  Google Scholar 

  75. Park JI. Rapid improvement of functional nausea and vomiting with mirtazapine in an elderly patient. Psychogeriatrics. 2019;19(6):614–5.

    Article  PubMed  Google Scholar 

  76. Song J, Lin N, Tian F, Li Y, Li Y. Successful treatment of gastroparesis with the antidepressant mirtazapine: a case report. J Nippon Med Sch. 2014;81(6):392–4.

    Article  PubMed  Google Scholar 

  77. Bhattacharjee D, Doleman B, Lund J, Williams J. Mirtazapine for postoperative nausea and vomiting: systematic review, meta-analysis, and trial sequential analysis. J Perianesth Nurs. 2019;34(4):680–90.

    Article  PubMed  Google Scholar 

  78. Thompson DS. Mirtazapine for the treatment of depression and nausea in breast and gynecological oncology. Psychosomatics. 2000;41(4):356–9.

    Article  CAS  PubMed  Google Scholar 

  79. Shibahara H, Uematsu N, Imai E, Tokura Y, Nishimura D. Effectiveness of mirtazapine for digestive symptoms in palliative care-retrospective study of 50 cases. Gan To Kagaku Ryoho. 2014;41(3):329–33.

    PubMed  Google Scholar 

  80. Kumar N, Barai S, Gambhir S, Rastogi N. Effect of mirtazapine on gastric emptying in patients with cancer-associated anorexia. Indian J Palliat Care. 2017;23(3):335–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Riechelmann RP, Burman D, Tannock IF, Rodin G, Zimmermann C. Phase II trial of mirtazapine for cancer-related cachexia and anorexia. Am J Hosp Palliat Care. 2010;27(2):106–10.

    Article  PubMed  Google Scholar 

  82. Theobald DE, Kirsh KL, Holtsclaw E, Donaghy K, Passik SD. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manag. 2002;23(5):442–7.

    Article  CAS  Google Scholar 

  83. Cankurtaran ES, Ozalp E, Soygur H, Akbiyik DI, Turhan L, Alkis N. Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer. 2008;16(11):1291–8.

    Article  PubMed  Google Scholar 

  84. Imai K, Ikenaga M, Kodama T, Kanemura S, Tamura K, Morita T. Sublingually administered scopolamine for nausea in terminally ill cancer patients. Support Care Cancer. 2013;21(10):2777–81.

    Article  PubMed  Google Scholar 

  85. Beadle KL, Helbling AR, Love SL, April MD, Hunter CJ. Isopropyl alcohol nasal inhalation for nausea in the emergency department: a randomized controlled trial. Ann Emerg Med. 2016;68(1):1–9 e1.

  86. Teran L, Hawkins JK. The effectiveness of inhalation isopropyl alcohol vs. granisetron for the prevention of postoperative nausea and vomiting. AANA J. 2007;75(6):417–22.

    PubMed  Google Scholar 

  87. Winston AW, Rinehart RS, Riley GP, Vacchiano CA, Pellegrini JE. Comparison of inhaled isopropyl alcohol and intravenous ondansetron for treatment of postoperative nausea. AANA J. 2003;71(2):127–32.

    PubMed  Google Scholar 

  88. Schwartz A. Comparison of inhalation of isopropyl alcohol vs promethazine in the treatment of postoperative nausea and vomiting (PONV) in patients identified as high risk for developing PONV. AANA J. 2009;77(6):417–8 author reply 8.

  89. Pellegrini J, DeLoge J, Bennett J, Kelly J. Comparison of inhalation of isopropyl alcohol vs promethazine in the treatment of postoperative nausea and vomiting (PONV) in patients identified as at high risk for developing PONV. AANA J. 2009;77(4):293–9.

    PubMed  Google Scholar 

  90. Cotton JW, Rowell LR, Hood RR, Pellegrini JE. A comparative analysis of isopropyl alcohol and ondansetron in the treatment of postoperative nausea and vomiting from the hospital setting to the home. AANA J. 2007;75(1):21–6.

    PubMed  Google Scholar 

  91. Thamlikitkul L, Srimuninnimit V, Akewanlop C, Ithimakin S, Techawathanawanna S, Korphaisarn K, et al. Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin-cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study. Support Care Cancer. 2017;25(2):459–64.

    Article  PubMed  Google Scholar 

  92. Bhargava R, Chasen M, Elten M, MacDonald N. The effect of ginger (Zingiber officinale Roscoe) in patients with advanced cancer. Support Care Cancer. 2020;28(7):3279–86.

    Article  PubMed  Google Scholar 

  93. Barton DL, Thanarajasingam G, Sloan JA, Diekmann B, Fuloria J, Kottschade LA, et al. Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer. 2014;120(22):3575–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Spiegel DR, Webb K. A case of treatment refractory hyperemesis gravidarum in a patient with comorbid anxiety, treated successfully with adjunctive gabapentin: a review and the potential role of neurogastroentereology in understanding its pathogenesis and treatment. Innov Clin Neurosci. 2012;9(11–12):31–8.

    PubMed  PubMed Central  Google Scholar 

  95. Ul Huda A, Jordan RW, Daggett M, Saithna A. Pre-medication with Gabapentin is associated with significant reductions in nausea and vomiting after shoulder arthroscopy: a meta-analysis. Orthop Traumatol Surg Res. 2019;105(8):1487–93.

    Article  PubMed  Google Scholar 

  96. Liu B, Liu R, Wang L. A meta-analysis of the preoperative use of gabapentinoids for the treatment of acute postoperative pain following spinal surgery. Medicine (Baltimore). 2017;96(37):e8031.

    Article  CAS  Google Scholar 

  97. Guttuso T Jr, Shaman M, Thornburg LL. Potential maternal symptomatic benefit of gabapentin and review of its safety in pregnancy. Eur J Obstet Gynecol Reprod Biol. 2014;181:280–3.

    Article  CAS  PubMed  Google Scholar 

  98. Guttuso T Jr. Gabapentin’s anti-nausea and anti-emetic effects: a review. Exp Brain Res. 2014;232(8):2535–9.

    Article  CAS  PubMed  Google Scholar 

  99. Guttuso T Jr, Robinson LK, Amankwah KS. Gabapentin use in hyperemesis gravidarum: a pilot study. Early Hum Dev. 2010;86(1):65–6.

    Article  CAS  PubMed  Google Scholar 

  100. Carbone F, Van den Houte K, Goelen N, et al. Mechanism underlying symptom benefit with prucalopride in gastroparesis. Am J Gastroenterol. 2019;114(12):1920–1.

    Article  PubMed  Google Scholar 

  101. Carbone F, Van den Houte K, Clevers E, et al. Prucalopride in gastroparesis: a randomized placebo-controlled crossover study. Am J Gastroenterol. 2019;114(8):1265–74.

    Article  PubMed  Google Scholar 

  102. Hobson R, Farmer AD, Dewit OE, O’Donnell M, Hacquoil K, Robertson D, et al. The effects of camicinal, a novel motilin agonist, on gastro-esophageal function in healthy humans-a randomized placebo controlled trial. Neurogastroenterol Motil. 2015;27(11):1629–37.

    Article  CAS  PubMed  Google Scholar 

  103. Chapman MJ, Deane AM, O’Connor SL, et al. The effect of camicinal (GSK962040), a motilin agonist, on gastric emptying and glucose absorption in feed-intolerant critically ill patients: a randomized, blinded, placebo-controlled, clinical trial. Crit Care. 2016;20(1):232.

    Article  PubMed  PubMed Central  Google Scholar 

  104. Lembo A, Camilleri M, McCallum R, Sastre R, Breton C, Spence S, et al. Relamorelin reduces vomiting frequency and severity and accelerates gastric emptying in adults with diabetic gastroparesis. Gastroenterology. 2016;151(1):87–96 e6.

  105. Camilleri M, McCallum RW, Tack J, Spence SC, Gottesdiener K, Fiedorek FT. Efficacy and safety of relamorelin in diabetics with symptoms of gastroparesis: a randomized, Placebo-Controlled Study. Gastroenterology. 2017;153(5):1240–50 e2.

  106. Hasler WL. Newest drugs for chronic unexplained nausea and vomiting. Curr Treat Options Gastroenterol. 2016;14(4):371–85.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mater Health Services, Mater Research-University of Queensland, South Brisbane, QLD, 4101, Australia

    Janet Hardy BSc FRACP FRAChPM MD

  2. Geisinger Medical Center, Danville, PA, USA

    Mellar P Davis MD FCCP FAAHPM

Authors
  1. Janet Hardy BSc FRACP FRAChPM MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mellar P Davis MD FCCP FAAHPM
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Janet Hardy BSc FRACP FRAChPM MD.

Ethics declarations

Conflict of Interest

Janet Hardy has been supported by a grant from the Australian National Health and Medical Research Council (NHMRC), which funded a number of studies quoted in this article and undertaken by Dr. Hardy. Mellar P. Davis declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article contains studies with human subjects performed by Prof. Hardy and reviews published by Dr. Mellar and Prof. Hardy.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Palliative and Supportive Care

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hardy, J., Davis, M.P. The Management of Nausea and Vomiting Not Related to Anticancer Therapy in Patients with Cancer. Curr. Treat. Options in Oncol. 22, 17 (2021). https://doi.org/10.1007/s11864-020-00813-0

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11864-020-00813-0

Keywords

Search

Navigation